AstraZeneca presented data at the EHA 2025 Congress in Milan.

1 report, 0 independent Updated Jun 25

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Who's involved

What this event is mainly about

AstraZeneca

Keep exploring

Part of

On June 25, 2025, the FDA approved revumenib for acute leukemia, and data was presented at the EHA Congress in Milan. All 1 developments

The entities involved

AstraZeneca
British-Swedish pharmaceutical company
- AstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.Mon 11:04
- Pharmaceutical companies are adopting AI for clinical data gathering, product promotion, and prototyping.Sat 18:52

Coverage

Newest first; wire copies grouped

Jun 25Unknown outlet